Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

Inclusion Criteria

• •Patient must have histologically confirmed squamous cell carcinoma with primary site in the oral cavity.
• •Patient must have no distant metastasis in the pre-adjuvant radiotherapy evaluation.
• •Patient must have received surgical treatment with pathologically documented extracapsular spreading of lymph node.
• •Patient must have no CTCAE 4.0 grading≧2 acute adverse events from previous definite treatment at enrollment.
• •Patient must can be enrolled within 1 to 3 months after definite treatment.
• •Age between 20 and 70 years old;
• •Patient must have ECOG performance status score 0 or 1;
• •Patient must have adequate hematopoietic function which is defined as below:
• •1. white blood cell (WBC) ≥ 4,000/mm3;
• •2. platelet count ≥ 100,000/mm3;
• •3. absolute neutrophil count (ANC) ≥ 1,500/mm3;
• •Patients must have adequate hepatic function which is defined as below:
• •1. serum bilirubin level \< 1.5 mg/dl;
• •2. sGOT and sGPT \< 2.5 x ULN;
• •3. serum creatinine level \< 1.5 x ULN;
• •All women of childbearing potential must have a negative serum or urine pregnancy test prior to the start of study medication;
• •Patient with childbearing potential must agree to use a reliable contraceptive method during their participation in the study;
• •Patient must have the ability to understand and willingness to sign a written informed consent document.